Cord blood beyond transplantation: can we use the experience to advance all cell therapies?
Br J Haematol
; 194(1): 14-27, 2021 07.
Article
en En
| MEDLINE
| ID: mdl-33529385
ABSTRACT
Unrelated cord blood (CB) units, already manufactured, fully tested and stored, are high-quality products for haematopoietic stem cell transplantation and cell therapies, as well as an optimal starting material for cell expansion, cell engineering or cell re-programming technologies. CB banks have been pioneers in the development and implementation of Current Good Manufacturing Practices for cell-therapy products. Sharing their technological and regulatory experience will help advance all cell therapies, CB-derived or not, particularly as they transition from autologous, individually manufactured products to stored, 'off-the shelf' treatments. Such strategies will allow broader patient access and wide product utilisation.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Bancos de Sangre
/
Sangre Fetal
/
Tratamiento Basado en Trasplante de Células y Tejidos
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
País/Región como asunto:
America do norte
/
Europa
Idioma:
En
Revista:
Br J Haematol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos